BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31472446)

  • 1. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy.
    Pimentel I; Lohmann AE; Ennis M; Dowling RJO; Cescon D; Elser C; Potvin KR; Haq R; Hamm C; Chang MC; Stambolic V; Goodwin PJ
    Breast; 2019 Dec; 48():17-23. PubMed ID: 31472446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
    Goodwin PJ; Chen BE; Gelmon KA; Whelan TJ; Ennis M; Lemieux J; Ligibel JA; Hershman DL; Mayer IA; Hobday TJ; Bliss JM; Rastogi P; Rabaglio-Poretti M; Mukherjee SD; Mackey JR; Abramson VG; Oja C; Wesolowski R; Thompson AM; Rea DW; Stos PM; Shepherd LE; Stambolic V; Parulekar WR
    JAMA; 2022 May; 327(20):1963-1973. PubMed ID: 35608580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin intervention against ovarian toxicity during chemotherapy for early breast cancer: Study protocol for a randomized double-blind placebo-controlled trial.
    Zhang J; Ma X; Li Y; Liu R; Li Y; Zhang P; Ren W; Cui P; Wang B; Zhang M; Jin Y; Li X; Wang S
    Maturitas; 2020 Jul; 137():1-6. PubMed ID: 32498930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
    Nanni O; Amadori D; De Censi A; Rocca A; Freschi A; Bologna A; Gianni L; Rosetti F; Amaducci L; Cavanna L; Foca F; Sarti S; Serra P; Valmorri L; Bruzzi P; Corradengo D; Gennari A;
    Breast Cancer Res Treat; 2019 Apr; 174(2):433-442. PubMed ID: 30536182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32).
    Hershman DL; Chen BE; Sathe C; Parulekar WR; Lemieux J; Ligibel JA; Gelmon KA; Whelan TJ; Goodwin PJ
    Breast Cancer Res Treat; 2023 Jul; 200(1):93-102. PubMed ID: 37157006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.
    Ng K; Nimeiri HS; McCleary NJ; Abrams TA; Yurgelun MB; Cleary JM; Rubinson DA; Schrag D; Miksad R; Bullock AJ; Allen J; Zuckerman D; Chan E; Chan JA; Wolpin BM; Constantine M; Weckstein DJ; Faggen MA; Thomas CA; Kournioti C; Yuan C; Ganser C; Wilkinson B; Mackintosh C; Zheng H; Hollis BW; Meyerhardt JA; Fuchs CS
    JAMA; 2019 Apr; 321(14):1370-1379. PubMed ID: 30964527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
    Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
    JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
    Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
    Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
    Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
    JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
    Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
    Rugo HS; Stopeck AT; Joy AA; Chan S; Verma S; Lluch A; Liau KF; Kim S; Bycott P; Rosbrook B; Bair AH; Soulieres D
    J Clin Oncol; 2011 Jun; 29(18):2459-65. PubMed ID: 21555686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
    Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
    Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.